Ask AI
Advances in mCRPC

CE / CME

Advances in Metastatic Castration-Resistant Prostate Cancer: Biomarker-Driven Treatment Strategies and Emerging Therapeutic Approaches

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: July 20, 2026

Expiration: January 19, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Neal D. Shore, MD, FACS, discusses the evolving treatment landscape of advanced prostate cancer, with a focus on mCRPC, biomarker-guided therapy selection, radiopharmaceuticals, emerging targeted agents, and strategies to optimize patient outcomes through multidisciplinary care and shared decision-making.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with prostate cancer do you provide care for in a typical month? 

For those who practice in academic or community settings, please indicate your practice setting: